Cargando…

Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus

INTRODUCTION: Although the largest improvement in glycemic control occurs within the first 90 days of insulin therapy, little is known about early persistence on insulin therapy. This research aimed to identify predictors of early discontinuation and of subsequent restart of basal or mixture insulin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascher-Svanum, Haya, Lage, Maureen J., Perez-Nieves, Magaly, Reaney, Matthew D., Lorraine, Joanne, Rodriguez, Angel, Treglia, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065305/ https://www.ncbi.nlm.nih.gov/pubmed/24782063 http://dx.doi.org/10.1007/s13300-014-0065-z

Ejemplares similares

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
por: Liu-Seifert, Hong, et al.
Publicado: (2007)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
por: Faries, Douglas, et al.
Publicado: (2012)

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes
por: Perez-Nieves, Magaly, et al.
Publicado: (2018)

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs
por: Saundankar, Vishal, et al.
Publicado: (2016)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence
por: Kelin, Katarina, et al.
Publicado: (2011)

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation
por: Matza, Louis S, et al.
Publicado: (2012)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
por: Peng, Xiaomei, et al.
Publicado: (2011)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
por: Montgomery, William, et al.
Publicado: (2012)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Item response analysis of the Positive and Negative Syndrome Scale
por: Santor, Darcy A, et al.
Publicado: (2007)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
por: Wu, Jianmin, et al.
Publicado: (2021)

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
por: Shi, Lizheng, et al.
Publicado: (2009)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Costs of treating patients with schizophrenia who have illness-related crisis events
por: Zhu, Baojin, et al.
Publicado: (2008)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jlrfoiusujshqb6bu6hli6u5qt